Twenty-two strategic enterprises have signed agreements with the Office for Attracting Strategic Enterprises (OASES) to open or expand operations in Hong Kong. The latest group marks the sixth cohort under the government’s flagship investment attraction initiative since its launch in 2022, bringing the total number of strategic partners to more than 120. The South China…
Global drug maker Pfizer and biotech firm Amgen, each valued at more than HK$1 trillion (US$153 billion), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post has learned. A source said on Monday that these industry leaders were among companies from the fintech, cloud computing…
Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Over the past six months, shares of the top three biopharma ETFs have jumped well into double digits. The top biotech-focused ETF with $6.562 billion…